49results about How to "Increase drug release rate" patented technology

Provided herein is a PEA polymer blend and coatings or implantable devices formed therefrom. The PEA polymer blend is formed of a PEA polymer and a material capable of hydrogen bonding with the PEA. The PEA polymer blend can form a coating on an implantable device, one example of which is a stent. The coating can optionally include a biobeneficial material and/or optionally with a bioactive agent. The implantable device can be used to treat or prevent a disorder such as one of atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.

The invention provides a PLGA (polylactic acid-hydroxyacetic acid) nano-drug carrier which is composed of PLGA nano microsphere kernel and an anillic aldehyde crosslinked chitosan housing. A preparation method of the polylactic acid-hydroxyacetic acid copolymer nano-drug carrier is as follows: dispersing a PLGA organic phase which takes dichloromethane and alcohol as a mixed solvent in a water phase to prepare PLGA microspheres by taking PVA (polyvinyl acetate) as an emulsifier by virtue of an one-off emulsion process; then, adding the PLGA microspheres into chitosan liquor, so that the chitosan is adsorbed on the surfaces of the PLGA microspheres, and then adding the chitosan on the surfaces of anillic aldehyde crosslinked PLGA microspheres. The product has a certain pH environmental responsiveness, can realize controlled release of the drug according to in-vivo pH environmental changes, is high in stability, strong in up-taking capacity for microsphere-coated medicaments by the cells, and has very good application prospect in the drug carrier for treating tumors.

Methods for formulating a liposome comprised of a surfactant and a cryopreservative that can be frozen for long term stability, and upon thawing provides an immediate and sustained release delivery profile. Specific liposome formulations include anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.

The present invention relates to medicine material technology, and is especially one kind of antiphlogistic medicine and growth factor slow releasing system and its preparation process and application. The prepared nanometer fiber medicine carrying film may be used in surgical operation to resist inflammation as skin tissue engineering rack. As post-operational adhesion resisting film, the present invention is biodegradable and biocompatible and has antiphlogistic effect. At the same time, medicine is combined with growth factor in controlled release speed and used in skin tissue engineering to prevent inflammation and to release growth factor promoting skin cell regeneration and healing simultaneously. The present invention has wide application foreground in post-operational adhesion prevention and skin tissue engineering.

Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.

Provided is an oral pharmaceutical composition with improved bioavailability and pharmacokinetic properties of a drug, by increasing a bioabsorption rate and an in vivo retention time of an active ingredient via intestine-targeted formulation of a particular naphthoquinone-based compound, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, as an active ingredient.

The invention provides preparation and application of a nano diamond drug with high load and pH capable of controlling release of adriamycin. H2N-PEG-COOH is firstly used for decorating a nano diamond, an ND-PEG-COOH carrier is synthesized, adriamycin is physically absorbed under the condition of Na-citrate and natrium aceticum to obtain target drug nano diamond-polyethylene glycol-adriamycin/sodium citrate (ND-PEG-DOX/Na3Cit) or nano diamond-polyethylene glycol-adriamycin/natrium aceticum (ND-PEG-DOX/NaAc). In vitro drug release experiments, MTT experiments and experiments that flow cytometry tests cell taking in nano diamond drug show that ND-PEG-DOX/Na3Cit and ND-PEG-DOX/NaAc can induce a cancer cell to apoptosis, and the nano diamond drug can be applied in preparation of antineoplastic drugs.

The invention discloses a process for preparing chitosan-based self-assembled nano microcapsule and the pharmaceutical release and regulation method, wherein the nano pharmaceutical microcapsule is prepared through using N,N-dialkylated chitosan as the capsule material, employing modified retrograde evaporation method according to the principle of the self-assembly technique, i.e. carrying out a second supersonic operation before centrifugal separation. The obtained microcapsule has a dimension distribution between 100-250nm.

The invention discloses a preparation method of an exenatide microneedle. The preparation method comprises the following steps of: pouring an aqueous solution of a polymer material containing exenatide on a mould with a micropore matrix, filling all micropores with the polymer solution, performing freezing and thawing cycle on the mould poured with the exenatide solution for multiple times, and finally performing film uncovering and drying. Exenatide has the defects that the half-life period is relatively short, exenatide is administrated twice a day, tolerance needs to be established through multiple times of small-dose injection, and much inconvenience and pain are brought to patients due to frequent injection. An exenatide phase conversion microneedle transdermal patch not only can realize minimally invasive non-injection administration of exenatide, but also is relatively safe, more effective and convenient to use, improves the compliance of a patient, and is convenient for the patient to establish tolerance.

The present invention relates to oral pharmaceutical compositions comprising co-crystals of tramadol and celecoxib, processes for preparation of the same and their use as medicaments, more particularly for the treatment of pain.

The invention discloses a reduction response type ABC type segmented polymer as well as a preparation method and application thereof, and belongs to the technical field of a reduction response type medicine carrier. The hydrophilic monomethyl ether polyethylene glycol (mPEG), hydrophobic lactide (LA) and allyl glycidyl ether (AGE) are selected to be used as raw materials; then, sulfydryl-olefin light click reaction and ring opening polymerization are combined to synthetize a polymer mPEG-b-PAGESH-b-PLLA with hydrosulphonyl groups at the side chain; then, the self assembly is performed to forma micelle; under the existence of hydrogen peroxide, hydrosulphonyl groups are oxidized into disulfide bonds; finally, the reduction response type crosslinking micelle with high stability is synthesized. The crosslinking micelle with the disulfide bonds is favorable for reducing the medicine leakage and initial fast release; in addition, the reduction response performance is also realized in the pathological change positions; under the existence of reducing agents DTT and glutathione, the medicine release behavior of the crosslinking micelle is obviously accelerated, so that the treatment effect is improved.

The invention relates to a divalproex sodium enteric-coated tablet core as well as a preparation method and an application thereof. The divalproex sodium enteric-coated tablet core is used for dry granulation. The divalproex sodium enteric-coated tablet core comprises the following components: 20-70 percent of divalproex sodium, 10-70 percent of filling agent, 0.5-20 percent of disintegrating agent, 5-20 percent of antisticking agent, 0.5-10 percent of talcum powder and 0.5-5 percent of magnesium stearate, wherein the antisticking agent is selected from one or a combination of silicon dioxide, superfine silica powder and silicon dioxide precipitate. The divalproex sodium enteric-coated tablet core prepared by using the preparation method is complete in release in vitro, higher in in-vitro dissolution speed and release rate and high in quality and has better safety and safety. The dry granulation method has the advantages of simple, convenient and feasible process, low cost, easiness in mass production, environmental friendliness and the like.

The invention discloses a radix salviae miltiorrhizae gel patch for external use. The radix salviae miltiorrhizae gel patch comprises medical nonwoven fabric, a gel layer and an anti-sticking layer, wherein the gel layer is radix salviae miltiorrhizae gel, and the radix salviae miltiorrhizae gel is prepared from the following formula components by weight percent: 0.8-1.2% of tanshinone, 18-22% ofcarbomer, 45-50% of hydroxypropyl methyl cellulose, 15-20% of polyvinylpyrrolidone, 2-5% of a cross-linking agent, 1-3% of a surface active agent, 0.8-1.5% of a cosurfactant and 0.5-0.8% of a humidifying agent. According to the radix salviae miltiorrhizae gel patch, the carbomer is used as a gel substrate, the hydroxypropyl methyl cellulose and the polyvinylpyrrolidone which are taken as a penetration enhancer, the cross-linking agent and the surface active agent are added, and all the components are evenly mixed by adopting ultrasonic treatment, so that the drug release rate is increased; furthermore, the radix salviae miltiorrhizae gel patch for external use is free from irritation to skin.

The invention discloses chitosan microcapsule modified acrylic bone cement. The chitosan microcapsule modified acrylic bone cement is formed by mixing a solid phase and a liquid phase, wherein the solid phase comprises a bone tumor drug loaded chitosan microcapsule, an antibiotic loaded water-swellable P (MMA-AA) copolymer nano-microsphere and polymethyl methacrylate; the liquid phase comprises methyl methacrylate, an accelerant and a polymerization inhibitor. The invention further discloses a preparation method of the chitosan microcapsule modified acrylic bone cement. The preparation method comprises the following steps of: uniformly mixing the bone tumor drug loaded chitosan microcapsule, the antibiotic loaded water-swellable P (MMA-AA) copolymer nano-microsphere and polymethyl methacrylate to obtain the solid phase; uniformly mixing methyl methacrylate, the accelerant and the polymerization inhibitor to obtain the liquid phase; and uniformly mixing the solid phase and the liquid phase. The chitosan microcapsule modified acrylic bone cement has a remarkable value for treating postoperative bone tumors, and has relatively high drug loading capacity, drug release rate and drug accumulated release amount under the condition that the compressive strength is basically unchanged.

The invention relates to a method for modifying oxidized single-walled carbon nanohorns by virtue of povidone, in particular to a novel drug loading system for loading docetaxel based on a single-walled carbon nanohorn-povidone compound which is built up by virtue of a nano-precipitation method. Through non-covalent modification of the povidone on the single-walled carbon nanohorns, the dispersity and the stability of the single-walled carbon nanohorns in water and a phosphate buffer solution can be effectively improved. On the basis of a [pi]-[pi] effect, by loading an anti-tumor drug, namely the docetaxel, with the compound single-walled carbon nanohorn-povidone, the water insolubility of the docetaxel is effectively improved and biocompatibility is improved; and the drug loading system is high in drug loading rate and significant in sustained-release effects, and the application of the single-walled carbon nanohorns in the field of nano-biomedicine is expanded.

The invention discloses aesculin nano-suspension gel and a preparation method and application thereof. Aesculin and a stabilizer are made into an aesculin nano-suspension agent, a gel matrix, a moisturizer and a pH regulator are further added, and the aesculin nano-suspension gel is prepared. According to the aesculin nano-suspension gel prepared by combining a precipitation method with a microjethigh-pressure homogenization method, the drug solubility and skin permeability can be increased, transmembrane transport of the aesculin nano-suspension gel can be promoted, the administration dosageis decreased, the toxic and side effects are reduced, the better therapeutic effect can be exerted in the body advantageously, and the ability to pass through a lipid bilayer is improved.